

JAP20 Rec'd PCT/PTO 22 JUN 2006

Sheet 1 of 2

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Atty. Docket No. X16757	Serial No. <b>10/584692</b>
		First Applicant ALLAN Barrett, et al.	
		Filing Date	Group <b>1644</b>

### U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
	AA	US 6,277,375 B1	08-21-2001	Ward	
	AB	US 2004/002587 A1	01-01-2004	Watkins, et al	
	AC	US 6,737,056 B1	05-18-2004	Presta	
	AD	US 10/370,749	02-20-2003	Watkins, et al.	
	AE	US 2003/0158389 A1	08-21-2003	Idusogie, et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. 1	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	BA	WO 88/07089	09-22-1988	Medical Research Council		
	BB	WO 92/16562	10-01-1992	Lynxvale Limited		
	BC	WO 94/29351	12-22-1994	Celltech Limited		
	BD	WO 99/58572	11-18-1999	Cambridge University Technical Services Limited		
	BE	WO 02/060919 A2	08-08-2002	MedImmune, Inc.		
	BF	WO 2003/074679 A2	09-12-2003	Xencor, Inc.		
	BG	WO 2004/029207 A2	04-08-2004	Xencor, Inc.		
	BH	WO 2004/063351 A2	07-29-2004	Macrogenics, Inc.		
	BI	WO 2004/074455 A2	09-02-2004	Applied Molecular Evolution, Inc.		

Examiner Signature	/Chun Dahle/ (12/16/2008)	Date Considered	
--------------------	---------------------------	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.  
Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /C.D./

FORM PTO 1449 (modified)  INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Atty. Docket No. X16757	Serial No. <b>107584692</b>
		First Applicant ALLAN Barrett, et al.	
		Filing Date	Group 1644

	BJ	WO 2005/056606 A2	06-23-2005	Xencor, Inc.		
	BK	EP 0 227 110 B1	07-01-1987	Teijin Limited		

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. I	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.			T <sup>6</sup>
	CA	CLYNES, RA, et al., "Inhibitory Fc receptors modulate in vivo cytotoxicity against tumor targets", pgs. 443-446, Nature Medicine, April 2000, Vol. 6, No. 4			
	CB	DUNCAN, AR, et al., "Localization of the binding site for the human high-affinity Fc receptor on IgG", Nature, 1988, pgs. 563-564, Vol. 332			
	CC	IDUSOGIE EE, et al., "Engineered Antibodies with Increased Activity to Recruit Complement", The Journal of Immunology, 2001, pgs. 2571-2575, Vol. 166, No. 4			
	CD	PRESTA, LG, et al., "Engineering therapeutic antibodies for improved function", Biochemical Society Transactions, 2002, pgs. 487-490, Vol. 30, No. 4			
	CE	SHIELDS, RL, et al., "High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FcγR*", The Journal of Biological Chemistry, 2001, pgs. 6591-6604, Vol. 276, No. 9			
	CF	SONDERMANN, P, et al., "Molecular Basis for Immune Complex Recognition: A Comparison of Fc-Receptor Structures", The Journal of Molecular Biology, 2001, pgs. 737-749, Vol. 309, No. 3			
	CG	SONDERMANN, P, et al., "The 3.2-Å crystal structure of the human IgG1 Fc fragment -FcγRIII complex", Nature, July 20, 2000, pgs. 267-273, Vol. 406, No. 20			
	CH	STEPELEWSKI, Z, et al., "Biological Activity of Human—Mouse IgG1, IgG2, IgG3, and IgG4 Chimeric Monoclonal Antibodies with Antitumor Specificity", Proc. Natl. Acad. Sci., July 1988, pgs. 4852-4856, Vol. 85, No. 13			
	CI	WOLFENSTEIN-TODEL, C, et al., "The Amino-Acid Sequence of Heavy Chain Disease Protein Zuc Structure of the FC Fragment of Immuno Globulin G-3", pgs. 907-914, Biochemical and Biophysical Research Communications, 1976, Vol. 71, No. 4			
Examiner Signature	/Chun Dahle/ (12/16/2008)		Date Considered		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of

document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached. Burden Hours Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case.

Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.